Glenmark launches globally-renowned hair growth formula Nourkrin® in Russia

Deepthi | Myequity news | Date : 01-11-2018 10:15:00 IST

Glenmark Pharmaceuticals Ltd., a research-led globally integrated pharmaceutical company, today announced the launch of Nourkrin® in Russia. Nourkrin® is a globally- renowned, clinically-proven proteoglycan replacement formula, for addressing one of the key underlying causes of hair loss in males and females.

Nourkrin® Woman and Nourkrin® Man will be exclusively marketed in Russia by Glenmark Impex LLC, the Russian subsidiary of Glenmark Pharmaceuticals Ltd., under a licensing agreement with Denmark- headquartered firm Pharma Medico ApS.

Glenmark had already launched Nourkrin® Woman in India in early 2018.  Nourkrin® contains Marilex®, a unique and proprietary scientific formula, rich in specific proteoglycans essential for hair follicle growth. Nourkrin® is a proven formula based on more than 56 scientific studies and is recognized by leading regulatory agencies globally.

“We are very happy to launch Nourkrin for both women and men in Russia. It is a much awaited product, as the problem of hair loss affects quite a significant proportion of the population. Glenmark has a strong portfolio of dermatology products in Russia offering patients relief from different types of skin disorders for several decades and Nourkrin will be a great addition to this portfolio,” Csaba Kantor, Senior Vice President & Head - Asia, Russia & CIS, Glenmark Pharmaceuticals, said.


According to a survey conducted by market research firm GfK in 2017, 18.7 million women and 14.1 million men in Russia experienced hair loss over the preceding 12 months.

About Glenmark Pharmaceuticals Ltd:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory. The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.


More from Myequity